FDA Expands Breyanzi Use to Primary CNS Lymphoma
The label update removes prior limitations on the CAR T-cell therapy for patients with primary central nervous system lymphoma.
Updated on Nov. 17, 2026 in Cancer

The U.S. Food and Drug Administration approved a label update for lisocabtagene maraleucel (Breyanzi; liso-cel) that removes its limitations of use in patients with primary central nervous system lymphoma (PCNSL). Liso-cel is the second CAR T-cell therapy to have its limitations removed for this population, following a February 2026 update for axicabtagene ciloleucel (Yescarta; axi-cel).
Why it matters
The change lifts a restriction that had limited access to CAR T-cell therapy for a rare and aggressive form of lymphoma affecting the central nervous system. It applies to adult patients with large B-cell lymphoma who have refractory disease after first-line chemoimmunotherapy or relapse within 12 months of it.
The label covers adult large B-cell lymphoma patients with refractory disease after first-line chemoimmunotherapy or relapse within 12 months of it, and at least two lines of systemic therapy for relapsed or refractory disease. The extraction does not include the trial data underlying the PCNSL expansion.
The players
U.S. Food and Drug Administration
The FDA is the federal agency responsible for approving drugs and biologics and setting their prescribing labels in the United States.
Breyanzi (lisocabtagene maraleucel)
Breyanzi, also called liso-cel, is a CAR T-cell therapy developed by Bristol Myers Squibb for certain B-cell lymphomas.
Yescarta (axicabtagene ciloleucel)
Yescarta, also called axi-cel, is a CAR T-cell therapy developed by Kite Pharma that received a PCNSL label update in February 2026.
The details
The FDA's label update for liso-cel, a CAR T-cell therapy, removes the limitations of use for patients with primary central nervous system lymphoma. The approved indications already include diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Timeline
February 2026: FDA approved a label update removing limitations of use for axi-cel in PCNSL.
FDA approved the liso-cel label update removing PCNSL limitations.
Health Landscape
The liso-cel update follows the February 2026 FDA action on axi-cel, making it the second CAR T-cell therapy cleared for use in primary central nervous system lymphoma without the prior limitations. Together, the two label changes extend a class of cell-based cancer treatments into a population that had previously been restricted.
Patients with primary central nervous system lymphoma who previously fell outside the approved use of CAR T-cell therapy may now be eligible for liso-cel under the updated label. Eligibility still depends on prior treatment history, including refractory disease after first-line chemoimmunotherapy or relapse within 12 months of it.
The takeaway
The label change shows regulators are expanding access to CAR T-cell therapy for hard-to-treat lymphomas, but eligibility still hinges on specific prior-treatment criteria. Patients and clinicians should review the full prescribing information to confirm whether a given case fits the approved use.
Further reading
Explore more on Cancer developments and treatment approvals.
Source note: This article includes information reported by OncLive.






